Atrin Pharmaceuticals Adds Critical Genomics Capabilities in Advance of Initiating First Clinical Trial Through Ongoing Collaboration with Predictive Technology Group

NEXT STORY
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
PREV STORY
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

- Phase 2 clinical trial initiated to further evaluate NSI-566 as treatment for ischemic ...

author_avatar
NASDAQ Market News

Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017

WATERTOWN, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage ...

author_avatar
NASDAQ Market News

Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones

Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017Investigator-Sponsor Pauses ...

author_avatar
NASDAQ Market News